Grifols Egypt collects enough plasma to meet Egypt's immunoglobulin needs

MADRID, 21 Feb. (EUROPA PRESS) -

Grifols Egypt is already receiving enough donations to cover the current domestic need for immunoglobulins (Ig) in Egypt, the blood products company reported this Wednesday, highlighting that this is a "key milestone" in the country's plan to achieve strategic autonomy in plasma treatments.

In fact, Grifols Egypt hopes to double plasma collections this year.

In this way, Grifols has highlighted in a statement that its integrated platform for obtaining plasma and producing blood products in Africa is making "great progress" in achieving its goal of achieving local self-sufficiency in these essential treatments.

"Grifols Egypt is supplying increasing quantities of plasma-derived medicines such as immunoglobulins, albumin and coagulation factors. To date, more than 30,000 vials of these blood products have been delivered to Egyptian hospitals and the patients who depend on them," he said. underlined the company.

Nearly two years after starting to receive the first plasma donations, Grifols Egypt is about to inaugurate its tenth center of the twenty planned.

In total, eight of the network's centers have received certification from the International Plasma Quality Program (IQPP) of the Plasma Protein Therapeutic Association (PPTA), a validation that all centers will have and which, according to the company, "confirms the best practices in the sector through audits issued by third parties."

At the same time, Grifols has explained that the construction project of a new state-of-the-art production center of 105,000 square meters in the Medical City of the New Administrative Capital is still underway, a center that will have fractionation and purification plants, facilities logistics and will be Grifols' first fully automated plasma analysis laboratory in the world.

When at full capacity, Grifols Egypt will analyze more than one million plasma samples per year. Grifols Egypt's current workforce of more than 650 direct employees with highly-skilled jobs is expected to triple to 2,000 when all twenty planned donation centers are operational and the production facility is fully operational. operational.

"Since Grifols and the National Service Projects Organization of Egypt signed their historic agreement in 2020 to establish Grifols Egypt and the first integrated platform for plasma collection and production of blood products in Africa and the Middle East, the project has progressed steadily, including during the pandemic", the company has stressed.

This initiative is part of Grifols' global plasma self-sufficiency program, "a commitment to innovative public-private alliances to guarantee the sustainable and long-term supply of plasma-derived medicines."

This includes everything needed to safely collect, analyze and store plasma before transforming it into treatments for patients.

Grifols also has a long-term agreement with Canadian Blood Services, the national authority responsible for blood in Canada, to significantly increase the country's self-sufficiency in immunoglobulins through an all-Canadian collection and processing infrastructure.

"Grifols is extremely pleased to achieve self-sufficiency in critical immunoglobulin medicines for Egypt, the first step towards achieving full strategic autonomy across the entire class of plasma therapeutics," said Raimon Grifols, Corporate Director of Grifols.

For her part, Magdy Amin, CEO of Grifols Egypt, highlighted that Grifols Egypt plays a key role "in the country's firm commitment to achieving leadership in plasma and healthcare in Egypt and the broader geographic area."